IXICO (IXI.L) Stock Price

IXICO Price

LSE·CLOSED
0.08GBP+0.00 (+0.00 %)
Market closed

Revenue has compounded at 6.8% per year over the past 19 years to 6.53 M GBP. Earnings per share have grown at 30.2% per year over the last 3 years. IXICO's net margin stands at -25.3%, down from 16.4% several years earlier. Analysts set a median price target of 26.52 GBP, implying 33,050.0% above the current price. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 21% above its 52-week low.

IXICO stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of IXICO over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how IXICO stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing IXICO's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

IXICO Stock Price History
DateIXICO Price
8/7/20260.08 GBP
8/6/20260.08 GBP
8/5/20260.08 GBP
8/4/20260.08 GBP
7/31/20260.08 GBP
7/30/20260.08 GBP
7/29/20260.09 GBP
7/28/20260.09 GBP
7/27/20260.09 GBP
7/24/20260.09 GBP
7/23/20260.09 GBP
7/22/20260.09 GBP
7/21/20260.09 GBP
7/20/20260.09 GBP
7/17/20260.09 GBP
7/16/20260.08 GBP
7/15/20260.08 GBP
7/14/20260.08 GBP
7/13/20260.08 GBP
7/10/20260.09 GBP
7/9/20260.09 GBP
7/8/20260.09 GBP
7/7/20260.09 GBP
7/6/20260.08 GBP
7/3/20260.08 GBP
7/2/20260.08 GBP
7/1/20260.08 GBP
6/30/20260.08 GBP
6/29/20260.08 GBP
6/26/20260.08 GBP
6/25/20260.08 GBP
6/24/20260.08 GBP
6/23/20260.08 GBP
6/22/20260.08 GBP
6/19/20260.09 GBP
6/18/20260.09 GBP
6/17/20260.09 GBP
6/16/20260.09 GBP
6/15/20260.09 GBP
6/12/20260.09 GBP
6/11/20260.09 GBP
6/10/20260.09 GBP
6/9/20260.09 GBP
6/8/20260.09 GBP
6/5/20260.09 GBP
6/4/20260.09 GBP
6/3/20260.09 GBP
6/2/20260.09 GBP
6/1/20260.09 GBP
5/29/20260.09 GBP
5/28/20260.09 GBP
5/27/20260.09 GBP
5/26/20260.09 GBP
5/22/20260.09 GBP
5/21/20260.09 GBP
5/20/20260.09 GBP
5/19/20260.09 GBP
5/18/20260.07 GBP
5/15/20260.07 GBP
5/14/20260.07 GBP
5/13/20260.07 GBP
5/12/20260.07 GBP
5/11/20260.07 GBP
5/8/20260.07 GBP
5/7/20260.07 GBP
5/6/20260.07 GBP
5/5/20260.07 GBP
5/1/20260.07 GBP
4/30/20260.07 GBP
4/29/20260.07 GBP
4/28/20260.07 GBP
4/27/20260.07 GBP
4/24/20260.07 GBP
4/23/20260.07 GBP
4/22/20260.07 GBP
4/21/20260.07 GBP
4/20/20260.07 GBP
4/17/20260.07 GBP
4/16/20260.07 GBP
4/15/20260.07 GBP
4/14/20260.07 GBP
4/13/20260.07 GBP
4/10/20260.07 GBP
4/9/20260.07 GBP
4/8/20260.08 GBP
4/7/20260.08 GBP
4/2/20260.08 GBP
4/1/20260.08 GBP
3/31/20260.08 GBP
3/30/20260.08 GBP
3/27/20260.08 GBP
3/26/20260.08 GBP
3/25/20260.08 GBP
3/24/20260.08 GBP
3/23/20260.08 GBP
3/20/20260.08 GBP
3/19/20260.08 GBP
3/18/20260.08 GBP
3/17/20260.08 GBP
3/16/20260.08 GBP
3/13/20260.08 GBP
3/12/20260.08 GBP
3/11/20260.08 GBP
3/10/20260.08 GBP
3/9/20260.08 GBP
3/6/20260.08 GBP
3/5/20260.08 GBP
3/4/20260.08 GBP
3/3/20260.08 GBP
3/2/20260.08 GBP
2/27/20260.08 GBP
2/26/20260.08 GBP
2/25/20260.08 GBP
2/24/20260.08 GBP
2/23/20260.08 GBP
2/20/20260.08 GBP
2/19/20260.09 GBP
2/18/20260.09 GBP
2/17/20260.09 GBP
2/16/20260.09 GBP
2/13/20260.09 GBP
2/12/20260.09 GBP
2/11/20260.10 GBP
2/10/20260.10 GBP
2/9/20260.10 GBP
2/6/20260.10 GBP
2/5/20260.10 GBP
2/4/20260.10 GBP
2/3/20260.10 GBP
2/2/20260.10 GBP
1/30/20260.11 GBP
1/29/20260.11 GBP
1/28/20260.11 GBP
1/27/20260.11 GBP
1/26/20260.11 GBP
1/23/20260.11 GBP
1/22/20260.12 GBP
1/21/20260.12 GBP
1/20/20260.12 GBP
1/19/20260.12 GBP
1/16/20260.12 GBP
1/15/20260.12 GBP
1/14/20260.12 GBP
1/13/20260.12 GBP
1/12/20260.12 GBP
1/9/20260.12 GBP
1/8/20260.12 GBP
1/7/20260.12 GBP
1/6/20260.12 GBP
1/5/20260.12 GBP
1/2/20260.12 GBP
12/31/20250.12 GBP
12/30/20250.12 GBP
12/29/20250.12 GBP
12/24/20250.12 GBP
12/23/20250.12 GBP
12/22/20250.12 GBP
12/19/20250.12 GBP
12/18/20250.12 GBP
12/17/20250.12 GBP
12/16/20250.12 GBP
12/15/20250.12 GBP
12/12/20250.12 GBP
12/11/20250.12 GBP
12/10/20250.12 GBP
12/9/20250.12 GBP
12/8/20250.11 GBP
12/5/20250.11 GBP
12/4/20250.11 GBP
12/3/20250.11 GBP
12/2/20250.11 GBP
12/1/20250.11 GBP
11/28/20250.11 GBP
11/27/20250.11 GBP
11/26/20250.11 GBP
11/25/20250.11 GBP
11/24/20250.11 GBP
11/21/20250.11 GBP
11/20/20250.11 GBP
11/19/20250.11 GBP
11/18/20250.11 GBP
11/17/20250.11 GBP
11/14/20250.11 GBP
11/13/20250.11 GBP
11/12/20250.11 GBP
11/11/20250.11 GBP
11/10/20250.11 GBP
11/7/20250.11 GBP
11/6/20250.11 GBP
11/5/20250.11 GBP
11/4/20250.11 GBP
11/3/20250.12 GBP
10/31/20250.11 GBP
10/30/20250.11 GBP
10/29/20250.11 GBP
10/28/20250.11 GBP
10/27/20250.11 GBP
10/24/20250.12 GBP
10/23/20250.12 GBP
10/22/20250.12 GBP
10/21/20250.12 GBP
10/20/20250.12 GBP
10/17/20250.12 GBP
10/16/20250.12 GBP
10/15/20250.13 GBP
10/14/20250.12 GBP
10/13/20250.12 GBP
10/10/20250.12 GBP
10/9/20250.12 GBP
10/8/20250.12 GBP
10/7/20250.12 GBP
10/6/20250.12 GBP
10/3/20250.12 GBP
10/2/20250.13 GBP
10/1/20250.13 GBP
9/30/20250.13 GBP
9/29/20250.14 GBP
9/26/20250.14 GBP
9/25/20250.14 GBP
9/24/20250.12 GBP
9/23/20250.12 GBP
9/22/20250.12 GBP
9/19/20250.12 GBP
9/18/20250.12 GBP
9/17/20250.12 GBP
9/16/20250.12 GBP
9/15/20250.12 GBP
9/12/20250.12 GBP
9/11/20250.12 GBP
9/10/20250.12 GBP
9/9/20250.12 GBP
9/8/20250.12 GBP
9/5/20250.12 GBP
9/4/20250.12 GBP
9/3/20250.12 GBP
9/2/20250.12 GBP
9/1/20250.12 GBP
8/29/20250.12 GBP
8/28/20250.12 GBP
8/27/20250.12 GBP
8/26/20250.12 GBP
8/22/20250.12 GBP
8/21/20250.12 GBP
8/20/20250.12 GBP
8/19/20250.12 GBP
8/18/20250.12 GBP
8/15/20250.12 GBP
8/14/20250.12 GBP
8/13/20250.12 GBP
8/12/20250.12 GBP
8/11/20250.12 GBP
Access this data via the Eulerpool API
Get Free API Key

IXICO Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
7.56 M GBP
360,000.00 GBP
430,000.00 GBP
Jan 1, 2020
9.53 M GBP
860,000.00 GBP
950,000.00 GBP
Jan 1, 2021
9.19 M GBP
1.12 M GBP
1.51 M GBP
Jan 1, 2022
8.64 M GBP
910,000.00 GBP
1.03 M GBP
Jan 1, 2023
6.67 M GBP
-1.44 M GBP
-1.18 M GBP
Jan 1, 2024
5.77 M GBP
-2.15 M GBP
-2.00 M GBP
Jan 1, 2025
6.53 M GBP
-2.55 M GBP
-1.65 M GBP
Jan 1, 2026 (e)
7.73 M GBP
-2.58 M GBP
-1.66 M GBP

IXICO Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 10, 2026, 3:14 PM
 
REVENUEM GBP
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM GBP
EBITM GBP
EBIT MARGIN%
NET INCOMEM GBP
NET INCOME GROWTH%
SHARESM
2011201220132014201520162017201820192020202120222023202420252026e
–––3.003.003.004.005.007.009.009.008.006.005.006.007.00
––––––33.3325.0040.0028.57–-11.11-25.00-16.6720.0016.67
–––66.6733.3333.3350.0060.0057.1466.6766.6762.5050.0040.0050.0050.00
3.003.003.002.001.001.002.003.004.006.006.005.003.002.003.003.50
-8.00-9.00-5.00-1.00-1.00-2.00-1.00–––1.00–-1.00-2.00-2.00-2.00
–––-33.33-33.33-66.67-25.00–––11.11–-16.67-40.00-33.33-28.57
-7.00-7.00-4.00-2.00-1.00-2.00-1.00–––1.001.00-1.00-2.00-1.00-1.00
133.33–-42.86-50.00-50.00100.00-50.00–––––-200.00100.00-50.00–
6.936.936.9415.0615.0624.3526.9333.7646.8047.5550.4150.7648.3148.3189.4789.47
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales IXICO generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue IXICO retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare IXICO's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares IXICO has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against IXICO's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

IXICO stock margins

The IXICO margin analysis displays the gross margin, EBIT margin, as well as the profit margin of IXICO. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for IXICO.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
65.34 %
4.76 %
5.69 %
Jan 1, 2020
66.63 %
9.02 %
9.97 %
Jan 1, 2021
65.51 %
12.19 %
16.43 %
Jan 1, 2022
60.65 %
10.53 %
11.92 %
Jan 1, 2023
49.03 %
-21.59 %
-17.69 %
Jan 1, 2024
47.02 %
-37.36 %
-34.70 %
Jan 1, 2025
48.71 %
-39.09 %
-25.27 %
Jan 1, 2026 (e)
48.71 %
-33.33 %
-21.47 %

IXICO Stock Revenue, EBIT, Earnings per Share

The IXICO earnings per share therefore indicates how much revenue IXICO has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2019
0.16 GBP
0.01 GBP
0.01 GBP
Jan 1, 2020
0.20 GBP
0.02 GBP
0.02 GBP
Jan 1, 2021
0.18 GBP
0.02 GBP
0.03 GBP
Jan 1, 2022
0.17 GBP
0.02 GBP
0.02 GBP
Jan 1, 2023
0.14 GBP
-0.03 GBP
-0.02 GBP
Jan 1, 2024
0.12 GBP
-0.04 GBP
-0.04 GBP
Jan 1, 2025
0.07 GBP
-0.03 GBP
-0.02 GBP
Jan 1, 2026 (e)
0.09 GBP
-0.03 GBP
-0.02 GBP

IXICO business model & stock analysis

IXICO PLC is a leading company in the field of digital biomarker and data services in clinical development. The company was originally founded in London in 2004 and has since had a successful history in neurology and psychiatry research. IXICO's core competency lies in developing and commercially implementing innovative solutions in the field of digital biomarker analysis, data capture, and processing. Through the use of advanced image analysis, structural analysis, and cognitive assessment technologies, IXICO enables effective clinical development of drugs and therapies, particularly in the areas of neurological and psychiatric disorders. IXICO is organized into three main divisions: Digital Healthcare Analytics (DHA), Data Analytics Services (DAS), and Clinical Trial Technology Solutions (CTTS). Each division includes its own products and services tailored to meet the specific requirements and needs of customers. The Digital Healthcare Analytics division focuses on developing biomarker-based clinical software-as-a-service (SaaS) solutions. These are used for monitoring and diagnosing neurological disorders such as Alzheimer's, Parkinson's, and schizophrenia. The solutions developed are tailored to the needs of clinics, research institutions, and biopharmaceutical companies and significantly contribute to the improvement of patient analysis and treatment. The Data Analytics Services division includes a wide range of services for data capture, processing, and analysis. This includes, for example, image and data analysis of clinical data, support for sponsors in data management and study monitoring, as well as consulting and training services. The purpose of this division is to help sponsors work in compliance with regulatory requirements and best practices in the pharmaceutical industry. IXICO's Clinical Trial Technology Solutions division offers a range of technology solutions to support the clinical research of pharmaceutical and biotechnology companies. This includes software solutions such as Neurostatus.net, a neurostatus toolkit for digital assessment of neurological patients, and TrialTracker, a SaaS solution that supports sponsors in the planning and conduct of studies. With its pioneering products and services, IXICO has numerous customers worldwide, including large pharmaceutical and biotech companies. The company also has partnerships with some of the most renowned academic institutions in Europe and North America and is proud to have been part of some of the most significant clinical studies in the field of neurology in recent years. Under the leadership of founder and CEO Derek Hill, IXICO has built an experienced and highly qualified team of scientists and industry experts over the years. The employees come from a variety of disciplines and industries and work closely together to develop innovative solutions and meet customer needs. The company expects to continue successfully focusing on the development of technology-based solutions in clinical research in the future.

IXICO SWOT Analysis

Strengths

Weaknesses: 1. Dependency on Key Clients: IXICO PLC relies heavily on a few key clients for a significant portion of its revenue, which poses a risk in case of client loss or reduced business volume. 2. Limited Market Presence: The company has yet to establish a strong presence in certain geographical markets, which limits its overall market reach and potential growth opportunities. 3. Relatively Small Company Size: IXICO PLC, being a relatively small company, may face challenges in competing with larger players in terms of resources and market influence.

Opportunities: 1. Advancements in Medical Technology: The continuous advancements in medical technology provide opportunities for IXICO PLC to develop and offer innovative solutions that cater to the evolving needs of the healthcare industry. 2. Increasing Healthcare Expenditure: The rising global healthcare expenditure creates a favorable market environment for IXICO to expand its customer base and increase its revenue potential. 3. Collaborations and Partnerships: Forming strategic collaborations and partnerships with research institutions, pharmaceutical companies, and other stakeholders can help IXICO PLC tap into new markets and enhance its product offerings.

Threats: 1. Intense Competition: IXICO operates in a highly competitive market with the presence of established players, which poses a threat to its market share and profitability. 2. Regulatory and Compliance Challenges: The healthcare industry is subjected to strict regulations and compliance requirements, which could potentially increase operational costs and limit the company's ability to deliver its services. 3. Economic Uncertainty: Economic downturns or financial instability in key markets can impact IXICO's business as organizations may reduce their spending on healthcare-related services during such periods.

Weaknesses

Opportunities: 1. Advancements in Medical Technology: The continuous advancements in medical technology provide opportunities for IXICO PLC to develop and offer innovative solutions that cater to the evolving needs of the healthcare industry. 2. Increasing Healthcare Expenditure: The rising global healthcare expenditure creates a favorable market environment for IXICO to expand its customer base and increase its revenue potential. 3. Collaborations and Partnerships: Forming strategic collaborations and partnerships with research institutions, pharmaceutical companies, and other stakeholders can help IXICO PLC tap into new markets and enhance its product offerings.

Threats: 1. Intense Competition: IXICO operates in a highly competitive market with the presence of established players, which poses a threat to its market share and profitability. 2. Regulatory and Compliance Challenges: The healthcare industry is subjected to strict regulations and compliance requirements, which could potentially increase operational costs and limit the company's ability to deliver its services. 3. Economic Uncertainty: Economic downturns or financial instability in key markets can impact IXICO's business as organizations may reduce their spending on healthcare-related services during such periods.

Opportunities

Threats: 1. Intense Competition: IXICO operates in a highly competitive market with the presence of established players, which poses a threat to its market share and profitability. 2. Regulatory and Compliance Challenges: The healthcare industry is subjected to strict regulations and compliance requirements, which could potentially increase operational costs and limit the company's ability to deliver its services. 3. Economic Uncertainty: Economic downturns or financial instability in key markets can impact IXICO's business as organizations may reduce their spending on healthcare-related services during such periods.

IXICO Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

IXICO historical P/E ratio, EBIT multiple, and P/S ratio

IXICO annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

IXICO shares outstanding

The number of shares of IXICO was 89.47 M in 2025. This indicates how many shares IXICO is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2019
46.80 M Stocks
Jan 1, 2020
47.55 M Stocks
Jan 1, 2021
50.41 M Stocks
Jan 1, 2022
50.76 M Stocks
Jan 1, 2023
48.31 M Stocks
Jan 1, 2024
48.31 M Stocks
Jan 1, 2025
89.47 M Stocks
Jan 1, 2026 (e)
89.47 M Stocks

IXICO stock splits

In IXICO's history, there have been no stock splits.

Current IXICO forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
88.89 % (8)
Hold
11.11 % (1)
Sell
0.00 % (0)
12M Price Target
0.27
Last Price
0.08
Currency
GBP
12M Return Potential
231.50 %
LTM Return
0 %

IXICO shareholder structure

% Name
9.61972%
Maven Capital Partners UK LLP
Maven Capital Partners UK LLP
0.94685%
Hardsteel, Ltd.
Hardsteel, Ltd.
0.69983%
Sarner (Marcus)
Sarner (Marcus)
0.33097%
Bejerano (Abraham)
Bejerano (Abraham)
0.19840%
Corob (Sidney)
Corob (Sidney)
0.18432%
Charterhouse Square Finance Company Limited
Charterhouse Square Finance Company Limited

IXICO Executives and Management Board

5 members · avg. age 53 · 40 % women

GN

Mr. Grant Nash (47)

Chief Financial Officer, Executive Director, Company Secretary · since 2019

221,000.00 GBP

Management

BG

Mr. Bram Goorden (51)

Chief Executive Officer, Executive Director · since 2024

44,000.00 GBP

Board of Directors

MW

Mr. Mark Warne (48)

Non-Executive Independent Chairman of the Board

47,000.00 GBP
DA

Dr. Dipti Amin (61)

Non-Executive Independent Director

31,000.00 GBP
KR

Ms. Katherine Rogers (58)

Senior Non-Executive Independent Director

31,000.00 GBP

IXICO Supply Chain

IXICO Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
4 companies
#NameTrend
1
Cyclerion Therapeutics
Customer·Biotechnology·US
-0.72
-0.01
0.32
0.77
0.92
0.54
2
Takeda Pharmaceutical
Supplier·Customer·Pharmaceuticals·JP
0.46
0.52
-0.66
-0.87
0.13
0.30
#NameTrend
1
Microsoft
Supplier·Customer·Software·US
-0.46
-0.11
-0.38
0.78
-0.27
-0.65
2
Gresham House
Supplier·Customer·Capital Markets·GB
-0.86
-0.13
-0.83
-0.35
-0.02
-0.40

Frequently asked questions about IXICO

IXICO PLC is a leading provider of digital technologies in healthcare, specializing in the application of artificial intelligence and data analytics to neurology. Their business model revolves around pioneering digital biomarkers and delivering innovative software solutions to biopharmaceutical and healthcare companies worldwide. IXICO PLC's unique platform allows for the collection, analysis, and interpretation of imaging and wearable sensor data, enabling efficient and accurate evaluation of neurodegenerative diseases. With a strong focus on research and development, IXICO PLC aims to provide valuable insights and assist in the development of new treatments for neurological disorders.

IXICO PLC is primarily active in the healthcare and pharmaceutical industries.

The main competitors of IXICO PLC in the market include companies such as Biogen Inc., Evidera, and ICON plc.

IXICO PLC is a leading provider of digital technologies to the global pharmaceutical industry. Established in 2004, IXICO's expertise lies in utilizing artificial intelligence and machine learning to derive valuable insights from medical imaging and digital biomarker data. The company specializes in providing clinical trial services and neuroimaging analysis solutions, enabling efficient and accurate assessment of neurodegenerative diseases. With a strong focus on research and development, IXICO's innovative technologies have been employed in several clinical trials worldwide. Over the years, IXICO has earned a reputation for its cutting-edge solutions, contributing significantly to advancements in precision medicine.

IXICO PLC has achieved several significant milestones. Notably, the company has made considerable progress in the field of data analytics and biomarker services for neuroscience clinical trials. IXICO PLC has successfully developed and validated novel algorithms and software platforms that provide accurate and reliable biomarker measurements. Additionally, the company has established strong partnerships with leading pharmaceutical and biotech companies, providing them with valuable insights and support in their research and development efforts. Moreover, IXICO PLC has consistently demonstrated its commitment to innovation and excellence, earning recognition and accolades from the industry.

IXICO PLC is primarily present in the United Kingdom, the United States, and Europe.

IXICO PLC represents core values of innovation, scientific excellence, and data-driven solutions in the field of data analytics for neuroscience. The company upholds a corporate philosophy focused on enhancing clinical research outcomes through advanced technology and specialized expertise. By leveraging its proprietary imaging and digital biomarker platform, IXICO PLC enables pharmaceutical companies and research organizations to better understand diseases affecting the brain. Their commitment to reliable and high-quality data analysis supports the development of novel treatments and therapies. With a strong emphasis on collaboration and continuous improvement, IXICO PLC strives to make a meaningful impact in neuroscience research and contribute to improving patients' lives.

Analysts currently set an average price target of 26.52 GBP for the IXICO stock (median: 26.52 GBP), implying +231.5 % versus the latest price. The consensus is based on 9 analyst ratings.

IXICO Analyst Price Targets 2026

9 analysts currently rate the IXICO stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect IXICO to generate revenue of 7.73 M GBP and earnings per share of -0.02 GBP.

IXICO Analyst Price Targets 2026

Converted at the current exchange rate, the IXICO share trades at 0.09 EUR (0.08 GBP).

The IXICO share (IXI.L) is listed on 4 stock exchanges, including: Frankfurt (PYPB.F), London (IXI.L), London (IXI.L).

IXICO PLC is a company specialized in digital health, with a business model that aims to offer innovative solutions for supporting clinical trials and diagnosing neurological diseases. The company is divided into different divisions, each offering specific products and services. The first division of IXICO is contract research. The company provides a comprehensive range of services to support companies in conducting clinical trials. This includes brain imaging, quantitative data analysis, and statistical evaluation of studies. Customers such as pharmaceutical and biotech companies can benefit from the company's expertise to evaluate the effectiveness of drugs and optimize study designs. Another division of IXICO is software solutions. The company develops and markets a wide range of software products aimed at supporting the diagnosis and monitoring of neurodegenerative diseases. The product range includes automated image analysis tools and algorithms for analyzing data obtained from neurological imaging techniques such as MRI and CT. Another division of the company is the provision of clinical trials to patients, as well as medical education. IXICO offers expertise and support in study design, decision-making, and the conduct of clinical trials. This can include training sessions and educational materials. The company primarily specializes in neurological diseases, such as multiple sclerosis, Alzheimer's, stroke, and Parkinson's. However, applications for diagnosing diseases affecting the nervous system are also a focus of the company. Overall, IXICO brings together a wealth of expertise that is crucial in the research, diagnosis, and treatment of neurological diseases. This includes scientific expertise in imaging techniques and statistics, as well as a comprehensive range of software products aimed at diagnosing neurological diseases more accurately and quickly. The company is dedicated to contributing to better treatment for patients worldwide and advancing medicine in the field of neurological diseases.

The expected revenue of IXICO is 7.73 M GBP. This figure is based on current financial data and reflects the company's business performance.

The expected profit of IXICO is -1.66 M GBP. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of IXICO is currently -4.31. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the IXICO stock.

The price-to-sales ratio (P/S) of IXICO is currently 0.93. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the IXICO stock.

The Eulerpool Quality Score for IXICO is 2/10.

The ISIN of IXICO is GB00BFXR4C20. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of IXICO is A2N478. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of IXICO is IXI.L. The ticker symbol is used to trade IXICO shares on the stock exchange.

IXICO paid dividends every year for the past 0 years.

IXICO is assigned to the 'Health' sector.

The dividends of IXICO are distributed in GBP.

All fundamentals and in-depth analysis of IXICO

Our stock analysis for IXICO stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IXICO. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

IXICO Stock
IXICO Revenue→
IXICO Stock
IXICO Net Income→
IXICO Stock
IXICO P/E→
IXICO Stock
IXICO P/S→
IXICO Stock
IXICO EBIT→
IXICO Stock
IXICO Dividend→
IXICO Stock
IXICO Directors Dealings→
IXICO Stock
IXICO Stocks→
IXICO Stock
IXICO Market capitalization→
IXICO Stock
IXICO Debt→
IXICO Stock
IXICO Liabilities→
IXICO Stock
IXICO Equity→
IXICO Stock
IXICO AAQS→
IXICO Stock
IXICO Employees→
IXICO Stock
IXICO ROE→
IXICO Stock
IXICO ROA→
IXICO Stock
IXICO ROCE→
IXICO Stock
IXICO News→
IXICO Stock
IXICO Analyst Price Targets→

Health Stocks

iZafe GroupIxensor CoJ B Chemicals and PharmaceuticalsIX BiopharmaJ Frontier CoIvision Tech SpAJack Nathan MedicalIVim TechnologyJacobio Pharmaceuticals Group CoIVF Hartmann HoldingJacobson Pharma CorporationITonisAll Stocks A–Z →